Impact of disease-free interval on recurrence in high-risk melanoma patients in a phase IIb trial of the tumor lysate particle loaded dendritic cell (TLPLDC) vaccine

Chick, RC; Bohan, PMK; Vreeland, TJ; Hickerson, AT; Cindass, JL; Hale, DF; Clifton, GT; Peoples, GE

CANCER RESEARCH, 2020; 80 (16):